Publication:
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

datacite.rightsrestricted
dc.contributor.authorYounossi, Zobair
dc.contributor.authorStepanova, Maria
dc.contributor.authorSanyal, Arun J
dc.contributor.authorHarrison, Stephen A
dc.contributor.authorRatziu, Vlad
dc.contributor.authorAbdelmalek, Manal F
dc.contributor.authorDiehl, Anna Mae
dc.contributor.authorCaldwell, Stephen
dc.contributor.authorShiffman, Mitchell L
dc.contributor.authorSchall, Raul Aguilar
dc.contributor.authorMcColgan, Bryan
dc.contributor.authorSubramanian, G Mani
dc.contributor.authorMyers, Robert P
dc.contributor.authorMuir, Andrew
dc.contributor.authorAfdhal, Nezam H
dc.contributor.authorBosch, Jaime
dc.contributor.authorGoodman, Zachary
dc.date.accessioned2024-12-13T15:47:24Z
dc.date.available2024-12-13T15:47:24Z
dc.date.issued2018-12
dc.description.abstractBACKGROUND & AIMS Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data. METHODS Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available. RESULTS A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06). CONCLUSIONS Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis. LAY SUMMARY Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.
dc.description.numberOfPages6
dc.description.sponsorshipDepartment for BioMedical Research, Hepatologie Forschung
dc.identifier.doi10.7892/boris.122127
dc.identifier.pmid30144554
dc.identifier.publisherDOI10.1016/j.jhep.2018.08.013
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/193267
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of hepatology
dc.relation.issn0168-8278
dc.relation.organizationDCD5A442BBC5E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C6DFE17DE0405C82790C4DE2
dc.subjectCryptogenic cirrhosis Fatty liver NAFLD NASH Outcomes
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleThe conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage1370
oaire.citation.issue6
oaire.citation.startPage1365
oaire.citation.volume69
oairecerif.author.affiliationDepartment for BioMedical Research, Hepatologie Forschung
oairecerif.author.affiliation2Universitätsklinik für Viszerale Chirurgie und Medizin, Hepatologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2019-10-22 23:15:06
unibe.description.ispublishedpub
unibe.eprints.legacyId122127
unibe.journal.abbrevTitleJ HEPATOL
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
1-s2.0-S0168827818322955-main.pdf
Size:
510.12 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections